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INTESTINAL smooth  muscle plays  a  major  role  in the
repair  of  injured  intestine  and  contributes  to  the
prostanoid  pool  during  intestinal  inflammatory
states.  Cyclooxygenase  (COX),  which  catalyzes  the
conversion of arachidonic acid to prostanoids exists
in two isoforms, COX-1 and COX-2. The purpose of
this study was to determine the relative contributions
of COX-1 and COX-2 in the production of prostanoids
by  human  intestinal  smooth  muscle  (HISM)  cells
when stimulated by interleukin-1b (IL-1b ) and lipo-
polsaccharide (LPS). Furthermore the effects of spe-
cific COX-1 and COX-2 inhibitors on the proliferation
of smooth muscle cells was also evaluated. Confluent
monolayer cultures of HISM cells were incubated with
IL-1b or LPS for 0–24 h while control cells received
medium alone.  PGE2 and  PGI2 as 6-keto-PGF1a and
LTB4 were measured by a specific radioimmunoassay.
COX  enzymes  were evaluated by  Western  immuno-
blotting.  Unstimulated  and  stimulated  cells  were
exposed  to  the  specific  COX-1  inhibitor  valerylsa-
licylic acid (VSA) and the COX-2 inhibitors NS-398 and
SC-58125. The effects of serum on proliferation were
then evaluated in the presence of each of the specific
COX inhibitors by incorporation of 3H-thymidine into
DNA. IL-1b and LPS increased both PGE2 and 6-keto-
PGF1a in a dose dependent  fashion with enhanced
production detected two hours following  exposure.
Neither  stimulus  stimulated  LTB4 release.  Immuno-
blot  analysis  using  isoform-specific  antibodies
showed  that  both  COX-1  and  COX-2  were  present
constitutively. Furthermore, COX-1 was upregulated
by each inflammatory stimulus. In a separate set of
experiments  cells  were  pretreated  with  either  the
selective COX-1 inhibitor VSA or the selective COX-2
inhibitors NS-398 or SC-58125 prior to treatment with
IL-1b or  LPS.  The  COX-1  and  COX-2  inhibitors
decreased  both  basal  and  IL-1b and  LPS  stimulated
prostanoid release. Spontaneous DNA synthesis was
present and serum consistently increased prolifera-
tion. 
3H-thymidine  incorporation,  stimulated  by
serum,  was  inhibited  by  both  COX-1  and  COX-2
inhibitors.  This  study  suggests  that  the  prostanoid
response  stimulated  by  proinflammatory  agents  of
gut-derived smooth muscle cells appears to be medi-
ated by both COX-1 and COX-2 enzymes. Proliferation
of smooth muscles cells also appears to be influenced
by both COX-1 and COX-2.
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Introduction
Cyclooxygenase (COX), also known as prostaglandin
H  synthase,  is  a  membrane  bound,  bifunctional
enzyme that catalyzes the conversion of arachidonic
acid  to  prostaglandin  G2 by  its  cyclooxygenase
activity and prostaglandin G2 to prostaglandin H2 by
peroxidase activity. It is the rate-limiting step in the
biosynthesis  of  the  biologically  active  and  physio-
logically  important  prostaglandins,  thromboxanes
and prostacyclin. COX exists in two distinct isoforms.
COX-1  exists in  most tissues and  is involved in  the
physiological  production  of  prostaglandins.  COX-2
has been demonstrated to be expressed in response
to many proinflammatory stimuli such as cytokines as
well  as  growth  factors.
1,2 Furthermore,  COX-2  is
thought  to  be  the  isoform  responsible  for  the
production of proinflammatory prostanoids in various
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stitutive and inducible COX enzymes has led to the
hypothesis  that  COX-2  is  primarily  responsible  for
prostaglandins produced in inflammation and COX-1
is involved in normal homeostasis.
3,4
Inflammatory  bowel  disease  (IBD)  is  a  chronic
debilitating  illness  of  the  gastrointestinal  tract  that
encompasses two primary forms of idiopathic intesti-
nal inflammation. Ulcerative colitis is a  disease that
affects primarily  the colon and rectum and involves
mucosal (epithelial) inflammation, while Crohns dis-
ease  affects  the  GI  tract  from  mouth  to  anus  and
involves  transmural  inflammation,  including  the
mucosal  and  muscle  layers.  As  a  result  of  the
amplification  of  the  inflammatory  process,  soluble
mediators such as eicosanoids play a significant role
in the pathogenesis and progression of IBD.
5 Produc-
tion  of  eicosanoids  are  increased  in  gut  mucosa  in
active IBD, whether assessed by in vitro culture of
mucosal biopsies, in vivo rectal dialysis, or whole-gut
lavage.
6,7 The production  of prostaglandins declines
in IBD patients treated with either corticosteroids or
sulfasalazine.  Although  prostaglandin  levels  in
mucosal  specimens  of  IBD  patients  declines  when
they  are  treated  with  NSAIDs,  there  is  no  clinical
improvement. In one study, selective COX-2 antago-
nists were shown to exacerbate colitis.
8
Human intestinal smooth muscle cells play a major
role  in  the  repair  of  injured  intestine. This  process
appears to be mediated by cytokines such as inter-
leukin-1B which induces collagenase expression and
inhibits  collagen  expression  in  human  intestinal
smooth muscle cells.
9,10 A common feature of Crohn’s
disease  is  a  narrowing  or  stricturing  of  the  bowel
lumen. Stricture formation remains a clinically impor-
tant complication of Crohn’s disease. Previous studies
have demonstrated that IL-1B enhances proliferation
of smooth muscle cells suggesting that the cytokine
produced during chronic inflammation may contrib-
ute to intestinal stricture formation.
11
Selective COX inhibitors are currently available. In
previous studies, utilizing specific COX-1 and COX-2
inhibitors, it has been found that selective COX-1 and/
or  COX-2  inhibitors  variably  inhibit  cell  prostanoid
formation stimulated by cytokines dependent on the
cell type and the stimulus.
12 –14 Proliferation of both
non-transformed epithelial cells and malignant intesti-
nal epithelial cells was inhibited by specific COX-2, but
not COX-1 inhibitors,
15 indicating a role for COX in
mitogenesis as well as demonstrating the role of COX
in prostanoid production by proinflammatory agents
in various cells such as enterocytes,
12 colonocytes
14
and  gallbladder  cells.
13 Limited  information  exists
regarding  the  activity  of  COX  enzymes  in  human
intestinal smooth muscle cells.
11 In the present study,
the effect of selective COX-1 and COX-2 inhibitors on
IL-1 and LPS stimulated prostanoid release by intestinal
smooth  muscle  cells  was  evaluated.  It  was  also
intended to ascertain if COX enzymes play a role in the
replication of human intestinal smooth muscle cells.
Methods
Cell isolation and culture
Human  Intestinal  Smooth  Muscle  cells  (HISM,  cata-
logue #1692-CRL) obtained from the American Type
Culture Collection (Rockville, MD) were maintained
at 37°C in an atmosphere of 5% CO2 and 100% relative
humidity.  Cells  were  split  at  a  ratio  of  1:2  upon
reaching confluence. Cells were detached using 0.5 g
porcine trypsin and 0.2 g EDTA tetrasodium/l Hanks
balanced salt solution (Sigma Chemical, St Louis-MO)
and then plated into 24 well plates for experiments or
into  175 cm
2 flasks  (Costar,  Cambridge,  MA)  for
propagation. The medium was changed every five to
seven  days. The medium used was Dulbeccos mod-
ified  Eagles  supplemented  with  10%  fetal  bovine
serum, 100 units/ml penicillin, 100 m g/ml streptomy-
cin and 0.25 m g/ml amphotercin B (Sigma). Viability of
the cells was verified by trypan  blue exclusion  and
morphology  was  evaluated  by  phase  contrast
microscopy.
Materials and protocol
The cells were plated at a density of 13 10
6 cells/well
and  after  24 h  were  washed  with  KRB  buffer  and
exposed  for  0–24 h  to  LPS  or  IL-1b dissolved  and
diluted in 95% oxygenated KRB buffer. The lipopoly-
saccharide  employed  was  Eschericia  coli lipopoly-
saccharide, CO 111:B4 (Sigma, St Louis, MO) and the
human recombinant IL-1b was obtained from Merck
DuPont Laboratories (Glenolden, PA). VSA (Cayman,
Ann Arbor, MI, 50 m M), SC-58125 (provided by Peter
Isakson, Monsanto Searle, St Louis, MO, 50 m M) and
NS-398  (Cayman,  50 m M)  were  dissolved  in  5%
sodium carbonate solution and diluted in KRB buffer
immediately before use. The concentrations of proin-
flammatory agents and COX inhibitors chosen were
based on previous dose response studies performed
utilizing intestinal epithelial cells.
12,13 To evaluate the
effect of the COX inhibitors the cells were pretreated
with VSA,  SC-58125,  or  NS-398  in  1 ml  fresh  tissue
culture media for 1 h prior to washing. Control cells
and  cells  exposed  to  LPS  or  IL-1b were  similarly
treated with fresh media for 1 h. At the conclusion of
the experiments the cells and buffer were collected
and  frozen  at  –80°C  until  the  assays  were
performed.
Western blot analysis
Cells  were  seeded  into  100 mm  dishes  (1.5  3
10
6/dish) and  grown  to confluency for  2  days. The
cultures  were  rinsed  with  serum-free  medium  and
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8 h. At  the  conclusion  of  the experiments  the cells
were  lysed  with  1% Triton  X-100,  120 mM  sodium
chloride,  25 mM  HEPES  (pH  7.4),  1 mM  phenyl-
methylsulfonyl  fluoride,  10 m g/ml  leupeptin,
10 m g/ml apoprotinin and 10 m g/ml antipapain. After
30 min the extracts were centrifuged at 12,000 g for
10 min  and  the  supernatants  solubilized  with  SDS-
PAGE  buffer  (68 mM  Tris-HCl,  pH  6.8,  5%
B-mercaptoethanol, 2% SDS, and 10% glycerol). The
samples  were  boiled  for  5 min  and  equal  amounts
were  applied  to  a  10%  SDS-polyacrylamide  gel.
Proteins were transferred to nitrocellulose and then
incubated  overnight  in  Tris-buffered  saline,  0.2%
Tween-20, and 10% nonfat  dry milk (BLOTTO). The
membranes were incubated with a rabbit  antiserum
generated  against  murine  COX-2  (1:1000)  or  sheep
COX-1 (1:1000). Following a three-hour incubation at
37°C,  the  membranes  were  washed  with  BLOTTO
and incubated with goat anti-rabbit IgG conjugated to
horseradish peroxidase (1:1000, Cappel) for 3 min at
37°C. Immunoreactive proteins were visualized using
the  enhanced  chemiluminescence  (ECL®,  Amer-
sham) method.
Eicosanoid measurements
To determine the cell protein concentration per well
the wells were thawed and washed with KRB buffer.
The  cells  were  freed  by  incubation  with  1%  col-
lagenase solution for 20min. The cells were scraped
from the wells and centrifuged at 200g for 20 min and
washed  with  KRB.  Protein  was  determined  by  the
method of Bradford
16 on cell specimens which were
solubilized with 0.1 N NaOH for 1 h at 37°C and then
sonicated for 10s. Bovine albumin was employed as
the  standard.  PGE2,  6-KPGF1a and  leukotriene  B4
(LTB4) assays were performed on the buffer solutions
in  duplicate  without  separation  by  a  competitive
enzyme assay  which utilizes an  acetylcholinesterase
tracer  (Cayman,  Ann  Arbor,  MI).  The  eicosanoid
concentrations  were  determined  by  spectrophoto-
metric analysis after addition of Ellmans reagent and
comparison to a standard curve. The concentrations
of  eicosanoids  were  expressed  as  picograms  per
milligram cell protein.
Proliferation studies
For the proliferation  experiments 13 10
3 cells were
seeded onto 96 well culture plates (Costar, Cambridge,
MA)  in  100 m l  of  Dulbelcco’s  minimum  essential
medium (DMEM, Sigma, St Louis, MO) with or without
10%  fetal  bovine  serum  (FBS,  Sigma). After  24 h  at
approximately 70% confluency, the cells were treated
with  either  the  COX-1  inhibitor VSA  (Cayman, Ann
Arbor, MI), the COX-2 inhibitor SC-58125 (Monsanto/
Searle, St Louis, MO) or indomethacin (Sigma, St Louis,
MO). After 24h of exposure the cells were washed
with  phosphate-buffered  saline  (PBS,  Sigma)  and
treated  with  the  same  types  of  media  and  agents,
including 1.5 uCi/well 
3H-thymidine (ICN, Costa Mesa,
CA) for 7 h. The cells were lysed with 100 ml of 0.1 M
NaOH and 0.2% Triton X-100 (Sigma) and the lysates
precipitated  with  20%  trichloroacetic  acid  (TCA,
Sigma). The precipitates were then harvested in  5%
TCA onto 240–1 glass-fiber filters (Cambridge, Water-
town, MA). The amount of isotope incorporated into
DNA was determined by liquid scintillation counting
using a Beckman LS 100 instrument.
Statistical analysis
The data is presented as mean±SEM. Statistical analy-
sis  was  performed  by  analysis  of  the  variance.
Differences between groups were determined by the
least  significant  difference. As  used  throughout  the
manuscript ‘significant’ indicates p<0.05.
Results
Western analysis
Western  blotting  of  resting  cells  (medium  alone)
demonstrated  both  constitutive  COX-1  and  COX-2
protein.  When  cells  were  incubated  with  LPS  or
IL-1b for  periods  of  up  to  24 h,  there  was  no
increase  in  expression  of  COX-2  protein.  However,
after 8h of LPS or IL-1b treatment, COX-1 expression
was increased (Fig. 1). Prestained molecular  weight
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FIG. 1. Western immunoblotting of COX-1 protein and COX-2
protein in unstimulated HISM cells and in cells stimulated for
8h with LPS (100m g/ml) and IL-1b (100 units/ml). Calcium
ionophore  (5m M)  was  also  evaluated.  Unstimulated  cells
demonstrated  constitutive  COX-1 and  COX-2 protein  was
increased by LPS or IL-1b . Unstimulated cells demonstrated
constitutive COX-2 protein. Both LPS and IL-1b induced COX-
2 protein formation.markers  were  run  on  the  same  gels  and  the  COX
immunoreactive bands shown corresponded to pro-
teins  approximately  70 kDa  in  size  consistent  with
COX enzymes. These results suggest that both COX-1
and COX-2 protein were both present constitutively
and COX-1 was further upregulated by proinflamma-
tory stimuli.
Basal prostanoid formation
When  unstimulated  HISM  cells  were  evaluated,  the
cells  produced  both  PGE2 and  PGI2,  the  latter
evaluated by measuring 6-keto-PGF1a (Table 1). The
HISM cell line produced significantly more PGE2 than
6-keto-PGF1a .  In  unstimulated  HISM  cells, VSA,  SC-
58125  and  NS-398  inhibited  both  PGE2 and  6-keto-
PGF1a formation,  suggesting  that  both  isoforms
contribute to basal prostanoid levels (Table 1). Basal
LTB4 levels were unaffected by COX inhibition.
Stimulated prostanoid formation
The proinflammatory stimulant IL-1b produced con-
centration  related  increases  in  PGE2 formation  by
HISM cells (Fig. 2). The increase in PGE2 produced by
IL-1b was  also  time  dependent  with  the  maximum
production seen at 8 h (Fig. 3). IL-1b (100 units/ml)
and LPS (100 m g/ml) stimulated PGE2 production by
HISM cells compared to control values (Tables 2 and
3). VSA, SC-58125  and NS-398  significantly decrease
IL-1b and LPS stimulated PGE2 production (Tables 2
and 3). LPS and IL-1b both also significantly increased
prostacyclin formation as evidenced by increases in
the  stable  metabolite  of  prostacyclin,  6-KPGF1a
(Tables 2 and 3). Similar to that seen with PGE2, VSA,
SC-58125  and  NS-398  significantly  decreased  stimu-
lated 6-KPGF1a formation. These results suggest that
both PGE2 and prostacyclin formation have variable
and not exclusive contributions by COX-1 and COX-2
in HISM cells. Neither LPS or IL-1b in the concentra-
tions  and  time  intervals  employed  in  this  study
significantly changed LTB4 production by HISM cells.
Also  evaluation  of  LTB4 levels  in  experiments  asso-
ciated with VSA, SC-58125, or NS-398 administration
with and without LPS or IL-1b was associated with no
significant  changes  in  LTB4 formation  (data  not
presented).
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Table 1. The effect of cyclooxygenase 1 and 2 inhibitors on
unstimulated  prostaglandin  E2  and  prostacyclin  (6-keto
PGF1a ) formation (ng/mg cell protein) by human intestinal
smooth muscle cells
Control VSA SC-58125 NS-398
PGE2 46.4±6.3 7.9±1.2* 9.1±1.3* 4.4±1.6*
6KPGFa 2.7±0.3 0.7±0.02* 0.8±0.02* 1.1±0.2*
Each value represents the mean±SEM of six values obtained from the
mean  of  duplicate  measurements  of  prostanoids  in  the  buffer
solution from six tissue culture wells containing 1 3 10
6 HISM cells
maintained in buffer solution, with or without COX inhibitors for 4h.
Asterisk indicates that the  value is significantly different  from the
control value.
FIG. 2. Dose response evaluation of IL-1b stimulated PGE2 formation in HISM cells 1 3 106 HISM cells were exposed to varying
concentrations of IL-1b for 4h. Each point represents the mean ± SEM of 6 values obtained from duplicate measurements of
PGE2 in buffer solution from six wells.Proliferation
The  effects  of  COX-1  and  COX-2  inhibitors  on
3H-thymidine  incorporation  in  HISM  cells  are
illustrated in Fig. 4. The concentrations of inhibitors
employed were based on previous studies with these
agents.  There  was  low-level  incorporation  of
3H-thymidine  into  DNA  by  HISM  lines  maintained
in  serum-starved  circumstances.  Serum  produced
a  significantly  increased  rate  of 
3H-thymidine
incorporation in HISM cells. Both VSA and SC-58125
significantly decreased 
3H-thymidine incorporation in
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FIG. 3. Evaluation of IL-1 stimulated PGE2 formation in HISM cells between 0–24h. HISM cells were exposed to 10 units/ml IL-1b
for the time periods indicated. Each point represents the mean±SEM of six values.
Table 2. The effect of cyclooxygenase 1 and 2 inhibitors on IL-1b stimulated prostaglandin E2 and prostacyclin (6-keto PGF1a
formation (ng/mg cell protein) by human intestinal smooth muscle cells
Control IL-1 IL-1 (100uM) plus 50uM
VSA SC-58125 NS-398
PGE2 46.4±2.3 106.1±5.4* 27.2±1.3# 51.5±4.6# 8.3+1.2#
6KPGF 2.7±0.7 12.4+3.1* 3.1±0.2# 0.8±0.1# 0.9±0.2#
Each value represents the mean ±SEM of six values obtained from the mean of duplicate measurements of prostanoids in the buffer solution
from six tissue culture wells containing 13 10
6 HISM cells. The cells were exposed to the cytokines with or without the COX inhibitors for four
hours. Asterisk indicates that the stimulated value is significantly different from the control value. The # sign indicates that the COX inhibitor
significantly altered the value stimulated by the cytokine.
Table 3. The effect of cyclooxygenase 1 and 2 inhibitors on LPS stimulated prostaglandin E2 and prostacyclin (6-keto PGF1a )
formation (ng/mg cell protein) by human intestinal smooth muscle cells.
Control LPS LPS (100m g/m) plus 50uM
VSA SC-58125 NS-398
PGE2 46.4±2.3 88.1±9.4* 22.4±2.4# 19.5±3.8# 6.1+2.0#
6KPGF 2.7±0.7 6.9+1.8* 0.5±0.06# 0.7±0.1# 0.9±0.3#
Symbols as for Table 2.HISM  cells  grown  in  10%  FBS  suggesting  that  both
COX-1 and COX-2 enzymes may contribute to human
smooth muscle cell proliferation.
Discussion
This study examined the induction by IL-1 and LPS of
COX protein and the effect of selective COX antago-
nists on prostanoid formation and on cell proliferation
in a human gut derived smooth muscle cell line. This
cell line appears to be a useful model for studying the
production  of  prostanoids  by  smooth  muscle  cells
during inflammatory states. Previous studies from our
laboratory employing gastrointestinal epithelial cells
have shown that trinitrobenzene sulfonic acid (TNB),
a hapten which produces experimental colitis, led to
significant  increases  in  PGE2 and  6-keto  PGF1a
release, but not leukotriene release; responses which
were  inhibited  by  indomethacin.
17 In  the  present
study, IL-1b and LPS stimulate prostanoid production
in HISM cells which was inhibited by selective COX
inhibitors. To investigate the mechanism by which IL-
1b and  LPS  enhance  the  production  of  PGE2 and
6-keto  PGF1a in  the  HISM  cell,  we  analyzed  the
expression of both COX-1 and COX-2 protein follow-
ing treatment. We found that IL-1b and LPS resulted in
the rapid and transient induction of both the COX-1
and COX-2 isoform.
Other investigators have examined the induction of
COX  isoforms  in  smooth  muscle  cells  other  than
those that are gut derived. Increased levels of several
pro-inflammatory  cytokines  including  IL-1  and TNF
have been found in bronchoalveolar lavage fluid from
symptomatic asthmatic patients. The effects of IL-1b ,
TNF and  IFN on  the induction  of COX isoforms in
cultured human airway smooth muscle cells demon-
strated that only IL-1b produced a time and concen-
tration dependent enhancement of PGE2 and 6-keto
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FIG. 4. The effect of specific COX inhibitors on serum enhanced 3H thymidine incorporation by HISM cells. The * indicates that
serum significantly increased 3H thymidine incorporation compared to serum free cells. The # indicates that the COX inhibitor
significantly decreased 3H thymidine incorporation compared to serum enhanced cells.PGF1a and  a  corresponding  increase  in  COX-2,  but
not  COX-1  activity.  Pretreatment  with  conventional
NSAIDs  and  selective  COX-2  inhibitors  completely
blocked IL-1b induced PGE2 release and both gluco-
corticoids and protein synthesis inhibitors suppressed
IL-1b induced  COX-2  induction. This  suggests  that
airway smooth muscle may be an important source of
prostaglandins in human airways and that COX-2 may
play  an  important  role  in  the  regulation  of  the
inflammatory  process  in  asthma.
18 A  similar  study
demonstrated that COX-2 expression and PGE2 forma-
tion were inhibited by an IL-1 receptor antagonist.
19
Both  studies  suggest  that  IL-1b produced  PGE2
formation  in  human  bronchial  smooth muscle  cells
that  is  mediated  by  de  novo expression  of  COX-2
enzyme.
The metabolism of arachidonic acid and production
of eicosanoids plays a vital role in the function of the
central  nervous  system,  especially  the  cerebrovas-
cular  function.  Smooth  muscle  cells  isolated  from
murine  cerebral  microvessels  produced  primarily
PGE2 and PGI2 in response to exogenous arachidonic
acid  and  calcium  ionophore.  Serum  deprivation  of
smooth muscle cells caused an 80–90% diminution in
both  PGE2 and  PGI2,  which was  restored  with  the
reintroduction of serum within 6 h. COX-1 and COX-2
mRNA was detectable in smooth muscle cells grown
in the presence of serum, but COX-2 mRNA was not
present in serum deprived cells. Readdition of serum
induced a massive increase in COX-2 mRNA with only
a small increase in COX-1 mRNA.
20 Cultured rat aortic
smooth muscle cells exhibited a  45-fold increase in
COX-2 mRNA levels after 2 h exposure to serum. This
was associated with increased COX-2 protein  and  a
3-fold increase in PGE2.
21 COX-1 protein is present in
freshly isolated myometrial cells and is not affected by
treatment with IL-1. Constitutive COX-2 is also pres-
ent and is unregulated by IL-1b treatment. Both basal
and IL-1b stimulated increase in COX-2 were reduced
by both a protein synthesis inhibitor and an inhibitor
of transcription.
22
The possible relationship of COX enzymes, prosta-
noids,  specific  COX-1  and  COX-2  inhibitors  and
standard  NSAIDs to decreasing the rate of  develop-
ment of gastrointestinal cancer is currently an active
area  of  investigation.  Previous work  from  our  labo-
ratory has demonstrated that in both nonmalignant-
and  malignant-derived  murine  intestinal  epithelial
cell lines there was evidence that the proliferation of
cells, stimulated by serum, was influenced by COX-
2,  but  not  COX-1  enzyme.
15 These  results  confirm
previous  in  vitro studies  demonstrating  the  inhibi-
tion  of  cell  proliferation  by  specific  COX-2  inhibi-
tors.
23–26 These experimental results support a  role
for COX-2 in intestinal epithelial cell mitogenesis and
provided  ground  work  for  similar  studies  with
smooth muscle cells. Unlike that seen with intestinal
epithelial cells, proliferation of HISM cells appears to
have  variable  contributions  from  both  COX-1  and
COX-2.
Crohn’s disease is an idiopathic, chronic inflamma-
tion of the gastrointestinal tract that causes narrowing
and  stricturing  of  the  small  and  large  intestine.
Although the mechanisms by which chronic inflam-
mation  promotes  stricture  formation  remain  ill
defined, it does appear to be associated histologically
with  a  hyperplasia  of  smooth  muscle  cells  and  an
increased  deposition  of  collagen  within  the  bowel
wall. The proinflammatory cytokines IL-1b caused a
significant  dose-dependent  increase  in  intestinal
smooth muscle cell proliferation.
27 This suggests that
proinflammatory cytokines produced during chronic
inflammation  may  enhance  the  proliferation  of
smooth  muscle  cells  and  may  contribute  to  the
narrowing  and  stricturing  observed  in  Crohn’s  dis-
ease. Smooth muscle cells in the intestinal wall play a
significant role in the healing of the injured intestine
and in the fibrosis that complicates Crohn’s disease.
27
IL-1b is  mitogenic  for  human  intestinal  smooth
muscle  cells  and  is  associated  with  a  concomitant
down regulation of collagen synthesis and secretion
and  an  augmentation  of  collegenase  expression.
28
Corticosteroids repress the induction of collagenase
expression and the inhibition of collagen secretion by
IL-1b in  HISM  cells.  We  feel  that  based  on  our
preliminary work, selective COX inhibition may be a
potential  avenue  for  addressing  the  problem  of
stricture formation  such that  changes in  prostanoid
milleu or even smooth muscle cell mitogenesis may
either  delay  or  ameliorate  progression  of  intestinal
Crohn’s disease.
The role of COX in prostanoid formation
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